Stuart Lind, MD
Professor, Medicine-Medical Oncology

Photo
Medical School:
  • MD, New York University School of Medicine (1976)
Undergraduate School:
  • AB, Cornell University (NY) (1972)
Internship:
  • University of Chicago/Northwestern University Program (1977)
Residency:
  • University of Chicago/Northwestern University Program, Chief Resident, Internal Medicine (1979)
Fellowships:
  • Brigham and Women's Hospital/Massachusetts General Hospital Program, Hematology and Oncology (1981)
  • University of Colorado, Blood Banking / Transfusion Medicine (2007)
Languages: English
Department: Medicine-Medical Oncology

Teaching

  • Professor (2006)
    School of Medicine, Medicine
  • Professor (2007)
    School of Medicine, Pathology

Publications

  • Lind SE. Phosphatidylserine is an overlooked mediator of COVID-19 thromboinflammation. Heliyon. 2021 Jan;7(1):e06033. PubMed PMID: 33495740
  • George G, Friedman KD, Curtis BR, Lind SE. Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination. Am J Hematol. 2021 Aug 1;96(8):E301-E303. PubMed PMID: 33989437
  • Beyer JT, Lind SE, Fisher S, Trujillo TC, Wempe MF, Kiser TH. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. J Thromb Thrombolysis. 2020 Feb;49(2):259-267. PubMed PMID: 31559512
  • Beyer JT, Lind SE, Fisher S, Trujillo TC, Wempe MF, Kiser TH. Evaluation of intravenous direct thrombin inhibitor monitoring tests: Correlation with plasma concentrations and clinical outcomes in hospitalized patients. J Thromb Thrombolysis. 2019 Sep 26. [Epub ahead of print] PubMed PMID: 31559512
  • McFarland CP, Lind SE. Thrombin Generation Biomarkers Decline With Parenteral Anticoagulation-An Overlooked Means of Anticoagulation Monitoring?. Clin Appl Thromb Hemost. 2018 Jul;24(5):708-717. PubMed PMID: 29439639
  • McFarland CP, Lind SE. Thrombin Generation Biomarkers Decline With Parenteral Anticoagulation-An Overlooked Means of Anticoagulation Monitoring?. Clin Appl Thromb Hemost. 2018 Jul;24(5):708-717. PubMed PMID: 29439639
  • Vanderbilt CM, McFarland C, Lind SE. Evaluation of a Reflex Testing Algorithm for Suspected Heparin-Induced Thrombocytopenia. Am J Clin Pathol. 2017 Nov 2;148(5):390-397. PubMed PMID: 29059268
  • Beyer J, Trujillo T, Fisher S, Ko A, Lind SE, Kiser TH. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb Hemost. 2016 Jul;22(5):423-8. PubMed PMID: 26842561
  • Wang S, Hannafon BN, Lind SE, Ding WQ. Zinc Protoporphyrin Suppresses ß-Catenin Protein Expression in Human Cancer Cells: The Potential Involvement of Lysosome-Mediated Degradation. PLoS One. 2015;10(5):e0127413. PubMed PMID: 26000787
  • Lind SE, Boyle ME, Fisher S, Ishimoto J, Trujillo TC, Kiser TH. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples. Am J Clin Pathol. 2014 May;141(5):665-74. PubMed PMID: 24713737
  • Wang S, Hannafon BN, Wolf RF, Zhou J, Avery JE, Wu J, Lind SE, Ding WQ. Characterization of docosahexaenoic acid (DHA)-induced heme oxygenase-1 (HO-1) expression in human cancer cells: the importance of enhanced BTB and CNC homology 1 (Bach1) degradation. J Nutr Biochem. 2014 May;25(5):515-25. PubMed PMID: 24613086
  • Wang S, Avery JE, Hannafon BN, Lind SE, Ding WQ. Zinc protoporphyrin suppresses cancer cell viability through a heme oxygenase-1-independent mechanism: the involvement of the Wnt/ß-catenin signaling pathway. Biochem Pharmacol. 2013 Jun 1;85(11):1611-8. PubMed PMID: 23523860
View All (12 Total) View Less

Practice Locations

UCHealth Hematology Clinic - Anschutz Medical Campus
1665 Aurora Ct
2nd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Internal Medicine, Board Certification (1979)
  • Medical Oncology, Board Certification (1981)
  • Hematology, Board Certification (1982, 2015)
  • Blood Banking / Transfusion Medicine, Board Certification (2007)
Conditions & Treatments
  • Blood / Lymphatic System
  • Blood / Lymphatic System - Blood Disorders
  • Cancers
  • Cancers - Leukemia (Adult Chronic)
  • Cancers - Lymphoma
  • Cancers - Myeloma
  • Blood / Lymphatic System - Bleeding Disorders
  • Blood / Lymphatic System - Clotting Disorders
Clinical Interests
I am interested in all aspects of hematology, including disorders of red blood cells, white blood cells, lymph nodes, platelets, bleeding and clottign disorders as well as cancers affecting the blood and lymph nodes.

General Information

Medical Schools:
  • MD, New York University School of Medicine (1976)
Undergraduate Schools:
  • AB, Cornell University (NY) (1972)
Internships:
  • University of Chicago/Northwestern University Program (1977)
Residency Programs:
  • University of Chicago/Northwestern University Program, Chief Resident, Internal Medicine (1979)
Fellowships:
  • Brigham and Women's Hospital/Massachusetts General Hospital Program, Hematology and Oncology (1981)
  • University of Colorado, Blood Banking / Transfusion Medicine (2007)
Languages: English
Department: Medicine-Medical Oncology
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;